DRG Epidemiology's coverage of acute lymphoblastic leukemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of acute lymphoblastic leukemia for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the developed world.

DRG Epidemiology's acute lymphoblastic leukemia forecast will answer the following questions:

  • Of all people diagnosed with acute lymphoblastic leukemia, how many in each country across the developed world are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of acute lymphoblastic leukemia over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.

In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following acute lymphoblastic leukemia subpopulations:

  • 2nd line dtp - older adults - bcr-abl- positive
  • 2nd line dtp - adolescents and young adults - bcr-abl- positive
  • 2nd line dtp - adolescents and young adults - bcr-abl-negative
  • 2nd line dtp - pediatric - bcr-abl-negative
  • 2nd line dtp - pediatric - bcr-abl-positive
  • 2nd line dtp -older adults - bcr-abl-negative
  • 3rd-and-4th line dtp - adolescents and young adults - bcr-abl- positive
  • 3rd-and-4th line dtp - adolescents and young adults - bcr-abl-negative
  • 3rd-and-4th line dtp - older adults - bcr-abl- positive
  • 3rd-and-4th line dtp - older adults - bcr-abl-negative
  • … and many more (details available on request).

Note: coverage may vary by country.

Table of contents

  • Acute Lymphoblastic Leukemia - Epidemiology - Americas Data
    • Introduction
      • Key Findings
        • Overview
          • Incidence of Acute Lymphoblastic Leukemia per 100,000 People of All Ages per Year in 2017 and 2027
          • Depiction of the Patient Flow for Acute Lymphoblastic Leukemia in Americas in 2017
          • Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Acute Lymphoblastic Leukemia over the Next Ten Years
          • Number of Additional Incident Cases of Acute Lymphoblastic Leukemia Incurred over 2017-2027 in the Countries Under Study
      • Epidemiology Data
      • Methods
        • Newly Diagnosed Incidence
        • Diagnosed Prevalence
        • Age Distribution
        • BCR-ABL Status
        • Immunophenotype
        • Precursor-B-Cell Immunophenotype
      • Reference Materials
        • Literature Review
          • Sources Included in the Analysis of Acute Lymphoblastic Leukemia
        • Risk/Protective Factors
          • Risk/Protective Factors for Acute Lymphoblastic Leukemia
        • Bibliography

    Author(s): Narendra Parihar; Nishant Kumar, MPH

    Narendra is an associate epidemiologist within the epidemiology team at Decision Resources Group. Narendra specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio.

    His qualifications include an MPH with specialization in Health Policy, Economics and Finance from the Tata Institute of Social Sciences, Mumbai, and a Bachelor’s degree in Dentistry from the Rajasthan University of Health Sciences.

    Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects.

    His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.


    Related Reports

    Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

    In this project, comissioned by Janssen in December, 2018, we have packaged our published estimates on the epidemiology of CLL - drug treated population across all the countries in Latin Ameri...

    View Details